LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
Analyse IA de LIDDS AB
Cliquez sur l’une des analyses ci-dessous pour obtenir des informations instantanées de l’IA via finAgent
Dernières analyses d’IA sur LIDDS AB
Aucun fil IA disponible pour cette entreprise pour le moment.